Cardiovascular Disease

LDL-TG’s Atherosclerosis Association

Out of tens of thousands of blood-based molecules and biomarkers, triglyceride-rich LDL molecules (LDL-TG) emerged as a direct cause of atherosclerotic coronary artery disease (ASCAD). 

LDL-C and Apo-B are widely known CVD risk factors, but it’s still unclear which specific risk factors underlie atherosclerosis, and to what extent. To investigate this, the authors applied a hypothesis-free Bayesian network analysis and genetic studies to 665 patients with suspected CAD.

The authors assessed simultaneous associations between genotypes, gene expression levels, circulating biomarkers, and CT-based atherosclerosis levels, finding that… 

  • LDL-TG was directly upstream from atherosclerosis in the Bayesian analysis.
  • LDL-TG was associated with atherosclerosis independent of well-known factors like age, sex, LDL-C and ApoB levels.
  • Genetic variations that “turned off” the hepatic lipase gene correlated with LDL-TG levels and atherosclerosis.
  • LDL-TG was positively linked to triglycerides, sd-LDL, and inflammatory markers.

What’s new? These findings are consistent with previous literature, but also reveal that LDL-TG has a central causal role in ASCAD, potentially as a result of abnormal hepatic lipase activity.  

The Takeaway 

The study suggests that triglyceride-rich LDL particles directly cause atherosclerotic CAD. With the recent introduction of a simple and fully automated method to measure LDL-TG levels, this biomarker may become an important tool in the clinical assessment of atherosclerosis. 

The analysis also showcases a promising new approach to evaluate genetic predisposition to ASCAD, and demonstrates how big “omics” data combined with AI has the potential to reveal novel treatment avenues.

Get the top cardiology stories right in your inbox

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team